{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Toxicity&page=3", "query": { "intervention": "Toxicity", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 8346, "total_pages": 835, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Toxicity&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Toxicity&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T02:20:10.835Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01718353", "title": "Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer Metastatic" ], "interventions": [ { "name": "DOCETAXEL (XRP6976)", "type": "DRUG" }, { "name": "CABAZITAXEL (XRP6258)", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 63, "start_date": "2013-03", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2017-11-20", "last_synced_at": "2026-10-25T02:20:10.835Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Indianapolis, Indiana + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01718353" }, { "nct_id": "NCT07762001", "title": "Study to Evaluate the Safety and Tolerability of AD-NP1 in Healthy Human Adult Volunteers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Maximum Tolerated Dose", "Dose Escalation" ], "interventions": [ { "name": "AD-NP1", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arjun Deb, MD", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 36, "start_date": "2026-06-02", "completion_date": "2028-05-01", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-25T02:20:10.835Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07762001" }, { "nct_id": "NCT00003712", "title": "CCI-779 in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Metastatic Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "temsirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2001-01", "completion_date": "2002-06", "has_results": false, "last_update_posted_date": "2012-08-09", "last_synced_at": "2026-10-25T02:20:10.835Z", "location_count": 2, "location_summary": "Rochester, Minnesota • San Antonio, Texas", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003712" }, { "nct_id": "NCT03883919", "title": "Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer", "Pancreas Cancer", "Cancer of the Pancreas" ], "interventions": [ { "name": "5-FU", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Liposomal Irinotecan", "type": "DRUG" }, { "name": "Paricalcitol", "type": "DRUG" }, { "name": "Serum and plasma blood samples", "type": "PROCEDURE" }, { "name": "Tumor biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2019-07-11", "completion_date": "2022-07-02", "has_results": false, "last_update_posted_date": "2022-10-05", "last_synced_at": "2026-10-25T02:20:10.835Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03883919" }, { "nct_id": "NCT00060411", "title": "A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mucinous Adenocarcinoma of the Colon", "Mucinous Adenocarcinoma of the Rectum", "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Signet Ring Adenocarcinoma of the Colon", "Signet Ring Adenocarcinoma of the Rectum", "Stage IIIA Colon Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Colon Cancer", "Stage IIIC Rectal Cancer", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2003-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-10-25T02:20:10.835Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060411" }, { "nct_id": "NCT02285439", "title": "Study of MEK162 for Children With Low-Grade Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Low-Grade Gliomas", "Malignant Neoplasms, Brain", "Soft Tissue Neoplasms" ], "interventions": [ { "name": "MEK162", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 105, "start_date": "2016-05-04", "completion_date": "2025-08-01", "has_results": true, "last_update_posted_date": "2025-10-07", "last_synced_at": "2026-10-25T02:20:10.835Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02285439" }, { "nct_id": "NCT03317119", "title": "Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colon Carcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Rectal Carcinoma", "RAS Family Gene Mutation", "Stage III Colon Cancer AJCC v7", "Stage III Colorectal Cancer AJCC v7", "Stage III Rectal Cancer AJCC v7", "Stage IIIA Colon Cancer AJCC v7", "Stage IIIA Colorectal Cancer AJCC v7", "Stage IIIA Rectal Cancer AJCC v7", "Stage IIIB Colon Cancer AJCC v7", "Stage IIIB Colorectal Cancer AJCC v7", "Stage IIIB Rectal Cancer AJCC v7", "Stage IIIC Colon Cancer AJCC v7", "Stage IIIC Colorectal Cancer AJCC v7", "Stage IIIC Rectal Cancer AJCC v7", "Stage IV Colon Cancer AJCC v7", "Stage IV Colorectal Cancer AJCC v7", "Stage IV Rectal Cancer AJCC v7", "Stage IVA Colon Cancer AJCC v7", "Stage IVA Colorectal Cancer AJCC v7", "Stage IVA Rectal Cancer AJCC v7", "Stage IVB Colon Cancer AJCC v7", "Stage IVB Colorectal Cancer AJCC v7", "Stage IVB Rectal Cancer AJCC v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Trifluridine and Tipiracil Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2018-04-11", "completion_date": "2023-07-14", "has_results": false, "last_update_posted_date": "2024-04-08", "last_synced_at": "2026-10-25T02:20:10.835Z", "location_count": 8, "location_summary": "Corona, California • Duarte, California • Lancaster, California + 5 more", "locations": [ { "city": "Corona", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Mission Hills", "state": "California" }, { "city": "Rancho Cucamonga", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03317119" }, { "nct_id": "NCT00843167", "title": "Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Precancerous Condition" ], "interventions": [ { "name": "broccoli sprout extract", "type": "DIETARY_SUPPLEMENT" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "21 Years to 120 Years · Female only" }, "enrollment_count": 54, "start_date": "2009-08", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2017-04-27", "last_synced_at": "2026-10-25T02:20:10.835Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00843167" }, { "nct_id": "NCT04169737", "title": "Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2020-07-29", "completion_date": "2028-07-09", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-25T02:20:10.835Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04169737" }, { "nct_id": "NCT02197572", "title": "Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Sapanisertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2014-09-15", "completion_date": "2019-02-28", "has_results": true, "last_update_posted_date": "2023-01-23", "last_synced_at": "2026-10-25T02:20:10.835Z", "location_count": 5, "location_summary": "Sarasota, Florida • St Louis, Missouri • The Bronx, New York + 2 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "The Bronx", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02197572" } ] }